{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:22:27Z","timestamp":1790479347419,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T00:00:00Z","timestamp":1590883200000},"content-version":"am","delay-in-days":396,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.lpm.2019.02.011","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T15:04:16Z","timestamp":1553699056000},"page":"503-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Quel est le VRAI risque au long cours des inhibiteurs de la pompe \u00e0 protons\u00a0?"],"prefix":"10.1016","volume":"48","author":[{"given":"Sophie","family":"Ribiere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Guillaumot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Barr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einas","family":"Abou Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilien","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Chaussade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Coriat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lpm.2019.02.011_bib0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.lpm.2019.02.011_bib0295","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1017\/ice.2014.39","article-title":"Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis","volume":"36","author":"Furuya-Kanamori","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"10.1016\/j.lpm.2019.02.011_bib0300","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ajg.2012.108","article-title":"Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis","volume":"107","author":"Kwok","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"35","key":"10.1016\/j.lpm.2019.02.011_bib0305","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","article-title":"Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis","volume":"23","author":"Trifan","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.lpm.2019.02.011_bib0310","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/gut.39.1.54","article-title":"Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study","volume":"39","author":"Thorens","year":"1996","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.lpm.2019.02.011_bib0315","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/bega.2001.0191","article-title":"Occurrence and significance of gastric colonization during acid-inhibitory therapy","volume":"15","author":"Williams","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.lpm.2019.02.011_bib0320","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/08923970009016425","article-title":"Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro","volume":"22","author":"Agastya","year":"2000","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2019.02.011_bib0325","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1365-2036.2000.014s1074.x","article-title":"A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions","volume":"14","author":"Yoshida","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.lpm.2019.02.011_bib0330","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/00003246-200205000-00026","article-title":"Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity","volume":"30","author":"Zedtwitz-Liebenstein","year":"2002","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2019.02.011_bib0335","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jhin.2017.08.017","article-title":"Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection","volume":"98","author":"Cao","year":"2018","journal-title":"J Hosp Infect"},{"issue":"1","key":"10.1016\/j.lpm.2019.02.011_bib0340","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00535-017-1369-3","article-title":"Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis","volume":"53","author":"Oshima","year":"2018","journal-title":"J Gastroenterol"},{"issue":"11","key":"10.1016\/j.lpm.2019.02.011_bib0345","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ajg.2016.343","article-title":"Proton pump inhibitors do not increase risk for Clostridium difficile infection in the intensive care unit","volume":"111","author":"Faleck","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.lpm.2019.02.011_bib0350","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.13.4.251","article-title":"Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro","volume":"13","author":"Giannella","year":"1972","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.lpm.2019.02.011_bib0355","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","article-title":"Systematic review of the risk of enteric infection in patients taking acid suppression","volume":"102","author":"Leonard","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"11\u201312","key":"10.1016\/j.lpm.2019.02.011_bib0360","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1365-2036.2011.04874.x","article-title":"Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection","volume":"34","author":"Bavishi","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.lpm.2019.02.011_bib0365","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1060028018760569","article-title":"The risk of community-acquired enteric infection in proton pump inhibitor therapy: systematic review and meta-analysis","volume":"52","author":"Hafiz","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.lpm.2019.02.011_bib0370","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.4238\/2015.July.3.25","article-title":"Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis","volume":"14","author":"Xu","year":"2015","journal-title":"Genet Mol Res GMR"},{"issue":"6","key":"10.1016\/j.lpm.2019.02.011_bib0375","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1742-1241.2011.02650.x","article-title":"Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients \u2013 a systematic review and meta-analysis","volume":"65","author":"Trikudanathan","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.lpm.2019.02.011_bib0380","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jgh.12065","article-title":"Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis","volume":"28","author":"Deshpande","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.lpm.2019.02.011_bib0385","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.dld.2015.12.009","article-title":"Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: A meta-analysis","volume":"48","author":"Yu","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.lpm.2019.02.011_bib0390","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2014.11.036","article-title":"Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study","volume":"62","author":"Terg","year":"2015","journal-title":"J Hepatol"},{"issue":"35","key":"10.1016\/j.lpm.2019.02.011_bib0395","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.4254\/wjh.v9.i35.1278","article-title":"Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis","volume":"9","author":"Miozzo","year":"2017","journal-title":"World J Hepatol"},{"issue":"9","key":"10.1016\/j.lpm.2019.02.011_bib0400","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/liv.13862","article-title":"Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis","volume":"38","author":"Tergast","year":"2018","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.lpm.2019.02.011_bib0405","doi-asserted-by":"crossref","first-page":"933","DOI":"10.5604\/01.3001.0012.7193","article-title":"Effect of proton pump inhibitors on mortality in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"17","author":"Hung","year":"2018","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.lpm.2019.02.011_bib0410","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/00365521.2018.1450442","article-title":"Proton pump inhibitors (PPIs) may cause gastric cancer \u2013 clinical consequences","volume":"53","author":"Waldum","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"16","key":"10.1016\/j.lpm.2019.02.011_bib0415","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM199604183341603","article-title":"Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication","volume":"334","author":"Kuipers","year":"1996","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lpm.2019.02.011_bib0420","doi-asserted-by":"crossref","first-page":"e017739","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.lpm.2019.02.011_bib0425","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","article-title":"Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study","volume":"67","author":"Cheung","year":"2018","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.lpm.2019.02.011_bib0430","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/0002-9343(92)90181-A","article-title":"Acute interstitial nephritis due to omeprazole","volume":"93","author":"Ruffenach","year":"1992","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.lpm.2019.02.011_bib0435","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1681\/ASN.2015121377","article-title":"Proton pump inhibitors and risk of incident CKD and progression to ESRD","volume":"27","author":"Xie","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.lpm.2019.02.011_bib0440","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"10","key":"10.1016\/j.lpm.2019.02.011_bib0445","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s10620-017-4725-5","article-title":"Associations of proton-pump inhibitors and H2\u00a0receptor antagonists with chronic kidney disease: a meta-analysis","volume":"62","author":"Wijarnpreecha","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.lpm.2019.02.011_bib0450","doi-asserted-by":"crossref","first-page":"e58837","DOI":"10.1371\/journal.pone.0058837","article-title":"The proton-pump inhibitor lansoprazole enhances amyloid beta production","volume":"8","author":"Badiola","year":"2013","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.lpm.2019.02.011_bib0455","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/jgh.13750","article-title":"Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review","volume":"32","author":"Batchelor","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.lpm.2019.02.011_bib0460","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/jgs.15073","article-title":"Proton pump inhibitor use and dementia risk: prospective population-based study","volume":"66","author":"Gray","year":"2018","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.lpm.2019.02.011_bib0465","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM198507113130202","article-title":"Calcium absorption and achlorhydria","volume":"313","author":"Recker","year":"1985","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2019.02.011_bib0470","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/156720109787846225","article-title":"Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo","volume":"6","author":"Sheraly","year":"2009","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.lpm.2019.02.011_bib0475","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.lfs.2018.12.058","article-title":"Proton pump inhibitors therapy and risk of bone diseases: an update meta-analysis","volume":"218","author":"Liu","year":"2019","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.lpm.2019.02.011_bib0480","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","article-title":"Proton-pump inhibitors and risk of fractures: an update meta-analysis","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos Int"},{"issue":"7","key":"10.1016\/j.lpm.2019.02.011_bib0485","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/ajg.2011.113","article-title":"Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies","volume":"106","author":"Ngamruengphong","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.lpm.2019.02.011_bib0490","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.113.003602","article-title":"Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine","volume":"128","author":"Ghebremariam","year":"2013","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.lpm.2019.02.011_bib0495","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lpm.2019.02.011_bib0500","doi-asserted-by":"crossref","first-page":"e0124653","DOI":"10.1371\/journal.pone.0124653","article-title":"Proton pump inhibitor usage and the risk of myocardial infarction in the general population","volume":"10","author":"Shah","year":"2015","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.lpm.2019.02.011_bib0505","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.10.042","article-title":"No increase in risk of acute myocardial infarction in privately insured adults prescribed proton pump inhibitors vs histamine-2\u00a0receptor antagonists (2002\u20132014)","volume":"154","author":"Landi","year":"2018","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.lpm.2019.02.011_bib0510","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/apt.14955","article-title":"Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel","volume":"48","author":"Batchelor","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.lpm.2019.02.011_bib0515","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lpm.2019.02.011_bib0520","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/cir767","article-title":"Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed","volume":"54","author":"Hermos","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.lpm.2019.02.011_bib0525","first-page":"797","article-title":"Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)","volume":"97","author":"Scheiman","year":"2011","journal-title":"Heart Br Card Soc"},{"issue":"6","key":"10.1016\/j.lpm.2019.02.011_bib0530","doi-asserted-by":"crossref","first-page":"e0128004","DOI":"10.1371\/journal.pone.0128004","article-title":"Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis","volume":"10","author":"Lambert","year":"2015","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.lpm.2019.02.011_bib0535","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","article-title":"Proton-pump inhibitor use and the risk for community-acquired pneumonia","volume":"149","author":"Sarkar","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.lpm.2019.02.011_bib0540","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gutjnl-2013-304738","article-title":"Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis","volume":"63","author":"Filion","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.lpm.2019.02.011_bib0545","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/joim.12826","article-title":"Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study","volume":"285","author":"Tran-Duy","year":"2019","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.lpm.2019.02.011_bib0550","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.11.023","article-title":"Proton pump inhibitor and histamine-2\u00a0receptor antagonist use and iron deficiency","volume":"152","author":"Lam","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.lpm.2019.02.011_bib0555","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.06.006","article-title":"Proton pump inhibitors decrease phlebotomy need in HFE Hemochromatosis: double-blind randomized placebo-controlled trial","volume":"153","author":"Vanclooster","year":"2017","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.lpm.2019.02.011_bib0560","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3109\/0886022X.2015.1057800","article-title":"Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies","volume":"37","author":"Cheungpasitporn","year":"2015","journal-title":"Ren Fail"},{"issue":"10","key":"10.1016\/j.lpm.2019.02.011_bib0565","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1681\/ASN.2004110989","article-title":"Novel TRPM6\u00a0mutations in 21\u00a0families with primary hypomagnesemia and secondary hypocalcemia","volume":"16","author":"Schlingmann","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"10.1016\/j.lpm.2019.02.011_bib0285","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/jama.2013.280490","article-title":"Proton pump inhibitor and histamine 2\u00a0receptor antagonist use and vitamin B12\u00a0deficiency","volume":"310","author":"Lam","year":"2013","journal-title":"JAMA"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219300582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219300582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:05:10Z","timestamp":1760105110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498219300582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0755498219300582"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2019.02.011","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quel est le VRAI risque au long cours des inhibiteurs de la pompe \u00e0 protons\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2019.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}